Dr. Erwin van Wijk is an Associate Professor at the Department of Otorhinolaryngology and the Donders Institute for Brain, Cognition and Behaviour (Radboud University Medical Center, Nijmegen, The Netherlands). He is head of the Usher Syndrome & Hereditary Hearing Loss Therapeutics Research Unit. From 2012 onwards, he has explored different therapeutic strategies to develop a genetic therapy for USH2A-associated retinal degeneration, thereby employing the zebrafish model for evaluating therapeutic efficacy. Using the method of antisense oligonucleotide-based splice modulation, he obtained pre-clinical proof of concept for the redirection of aberrant splicing caused by a common deep-intronic mutation in the USH2A gene. Furthermore, he explored the use of antisense oligonucleotides for the purpose of the skipping of the most frequently mutated exon in the USH2A gene, for which a phase 1/2 clinical trial was just successfully completed. The current work of his research team is dedicated to better understanding the molecular mechanisms underlying different clinical types of Usher syndrome, non-syndromic inherited retinal dystrophies and inherited hearing impairment, and to directly apply that knowledge for the development of new treatment strategies for the many visually and hearing impaired individuals worldwide.
Dr. Erwin van Wijk is an Associate Professor at the Department of Otorhinolaryngology and the Donders Institute for Brain, Cognition and Behaviour (Radboud University Medical Center, Nijmegen, The Netherlands). He is head of the Usher Syndrome & Hereditary Hearing Loss Therapeutics Research Unit. From 2012 onwards, he has explored different therapeutic strategies to develop a genetic therapy for USH2A-associated retinal degeneration, thereby employing the zebrafish model for evaluating therapeutic efficacy. Using the method of antisense oligonucleotide-based splice modulation, he obtained pre-clinical proof of concept for the redirection of aberrant splicing caused by a common deep-intronic mutation in the USH2A gene. Furthermore, he explored the use of antisense oligonucleotides for the purpose of the skipping of the most frequently mutated exon in the USH2A gene, for which a phase 1/2 clinical trial was just successfully completed. The current work of his research team is dedicated to better understanding the molecular mechanisms underlying different clinical types of Usher syndrome, non-syndromic inherited retinal dystrophies and inherited hearing impairment, and to directly apply that knowledge for the development of new treatment strategies for the many visually and hearing impaired individuals worldwide.